Aglaia Oncology Funds

Aglaia Oncology Funds is a private investment firm based in Bilthoven, Netherlands, focusing exclusively on early-stage investments in oncology drug development. The firm aims to translate high-potential research into commercially and clinically successful products by providing capital and expertise to emerging biotech companies. Aglaia's investment philosophy centers on impact investing, combining financial returns with social benefits by improving patient outcomes and quality of life.

The firm's strategy involves close collaboration with innovators and entrepreneurs to define strategic directions, de-risk projects, and make them attractive for licensing or acquisition. Aglaia's team has decades of experience in cancer research and oncology drug development, enabling them to identify and nurture breakthrough cancer treatments from initial research through clinical trials. The firm emphasizes socio-economic impact through its Life Sciences Impact Suite platform, ensuring that investments benefit both society and investors.

Aglaia has managed multiple funds, including Aglaia Oncology Fund II, which launched in 2014 with a target size of $80 to $100 million. The fund focuses on investing in biotechnology start-ups developing groundbreaking technologies aimed at preventing and curing cancer. Aglaia's commitment to impact investing is further demonstrated by the development of the Life Sciences Impact Suite, a tool enabling measurement and reporting of the social impact realized by investments, alongside financial performance. This suite covers over 50 parameters related to innovation, clinical trials, socio-economic aspects, and finance, providing transparency and accountability to investors and stakeholders.